Gene therapy access continues to challenge healthcare systems across Europe despite clear patient need and clinical promise. For families facing metachromatic leukodystrophy (MLD), an ultra-rare neurometabolic disease, timely treatment can mean the difference between normal development and rapid neurological decline. This article considers the recent discussion with Andreas Schuil published by PharmaBoardroom on practical obstacles, economic realities and policy adjustments required to improve gene therapy access for patients with rare conditions.

The Heavy Burden of Metachromatic Leukodystrophy

MLD affects roughly one in 100,000 children and stems from mutations in the ARSA gene. Without the arylsulfatase A enzyme, toxic sulfatides accumulate and destroy myelin throughout the brain and nervous system. Children initially develop normally before experiencing swift loss of speech, mobility, swallowing and sensory functions. Most die within five years of symptom onset. The condition places intense emotional strain on families and generates substantial long-term costs for intensive care and support services.

Orchard Therapeutics developed atidarsagene autotemcel, an autologous haematopoietic stem cell gene therapy. Clinicians collect the patient’s own stem cells, correct the genetic defect outside the body, and return them after conditioning chemotherapy. These modified cells can cross the blood-brain barrier and deliver lasting enzyme production. When given before symptoms advance, the treatment halts or slows disease progression. Yet such benefits reach patients only when systems enable swift gene therapy access.

Why One-Time Treatments Test Health Systems

European payers have grown accustomed to chronic therapies spread over years. A single administration that delivers lifelong benefit creates immediate budget impact even when lifetime cost analyses prove favourable. For ultra-rare diseases with tiny patient numbers, manufacturers must recover development costs through a single transaction that many budget holders find difficult to accommodate.

Autologous therapies add further complexity. Each dose depends on the individual patient’s cells, so qualified treatment centres form the first step in manufacturing. Companies must therefore train staff, establish quality agreements, organise complex logistics and maintain standards at centres that may treat only one or two patients per year. Cross-border arrangements become essential because not every country can sustain a specialised centre. These operational demands explain why consistent gene therapy access remains uneven despite regulatory approvals.

Current Access Patterns Across the Continent

Reimbursement exists in Germany, Italy, Spain, the United Kingdom, Benelux and Nordic countries through collaborative mechanisms. France has operated an early access programme for five years while full reimbursement discussions continue. In Eastern Europe, cross-border funding routes allow selected patients to travel to qualified centres elsewhere. These differences highlight how national frameworks, evidence standards and risk tolerance shape real-world availability.

Diagnosis usually occurs after symptoms appear or through family screening when an older sibling receives a diagnosis. The narrow therapeutic window makes speed critical. Newborn screening offers the clearest route to early identification. Norway now includes MLD in its national programme, while Austria runs a long-standing pilot and selected Italian regions have begun screening. The recent addition of MLD to the US Recommended Uniform Screening Panel provides further momentum. However, classic screening criteria require an approved and funded treatment before widespread adoption, creating a circular dependency that slows progress.

Legislative Proposals and Operational Reality

Revisions to European pharmaceutical legislation include a requirement for simultaneous launch across all 27 member states. For small organisations focused on ultra-rare diseases, this demand presents serious difficulties. Parallel reimbursement processes with divergent data requirements, timelines and decision criteria stretch limited resources and personnel. The same clinical package can receive markedly different interpretations across countries, making uniform launch unfeasible for many developers.

These rules risk reducing rather than expanding gene therapy access. Companies may delay or avoid certain markets entirely when the combined cost and uncertainty outweigh potential returns. Such outcomes would leave European patients waiting longer than those in the United States where prevalence is higher and strategic alignment between economic and health goals appears stronger.

Practical Steps for Decision-Makers

• Implement payment models that spread costs over time or tie reimbursement to measurable clinical outcomes, thereby aligning incentives with long-term value.
• Strengthen the Joint Clinical Assessment process so it reduces duplication and prevents convergence on the most restrictive evidence standards.
• Fund specialised centres of excellence for advanced therapy medicinal products to share infrastructure costs that individual manufacturers cannot sustain for very rare conditions.
• Accelerate newborn screening programmes once therapies receive approval and secure funding, recognising that early detection dramatically improves both clinical results and health economic returns.
• Formalise and finance cross-border treatment pathways as a standard feature of European cooperation rather than an occasional workaround.

Outlook for Sustainable Gene Therapy Access

Europe expresses clear ambition to lead in life sciences yet its current combination of fragmented reimbursement, high evidence thresholds and limited risk-sharing often produces the opposite effect. Without structural changes, the continent risks becoming a secondary market for innovations in ultra-rare diseases.

Clear clinical benefit provides the foundation for change. When health authorities and manufacturers focus on documented outcomes for conditions such as MLD, constructive dialogue becomes possible. The coming years will test whether European systems can evolve to match scientific progress. Targeted reforms in payment, assessment and infrastructure would allow more patients to benefit from gene therapy access while maintaining financial sustainability. Senior leaders in policy, health economics and market access now face concrete choices that will shape care for rare disease patients for decades ahead.